Gene 420

Company Overview

Snapshot

Founded in March 2018 by Ophir Nevo, Uri Aizik, Mark Fainstein, and Yoav Orlev, Gene 420 operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on developing its DNA-based recommendation platform for cannabis users.

Business overview

Gene 420 is a Health Tech & Life Sciences company that aims to enhance the safety and enjoyment of medicinal and recreational cannabis consumption. The company's core technology involves recommending specific cannabis products by analyzing users' DNA and questionnaire results. Gene 420 serves individual patients and consumers, as well as cannabis sellers, by providing a marketplace that matches products to customer needs. It operates within the digital healthcare, personalized medicine, and medical cannabis sectors, with a focus on digital therapeutics.

Company Intelligence Q&A

What is Gene 420's primary offering?

Gene 420 provides DNA-based recommendations for cannabis products, aiming to make medicinal and recreational cannabis consumption safer, smarter, and more enjoyable for users.

When was Gene 420 founded?

Gene 420 was founded in March 2018.

Who are the founders of Gene 420?

The co-founders of Gene 420 are Ophir Nevo, Uri Aizik, Mark Fainstein, and Yoav Orlev.

What markets does Gene 420 target?

Gene 420 targets geomarkets in Israel and the United States, serving both patients and recreational cannabis consumers.

What is the current product stage of Gene 420?

Gene 420's product is currently in its Beta stage, indicating it is undergoing testing and refinement before a full public release.